RRMS patients treated with Interferon beta-1alpha (IFNβ-1a) and fingolimod exhibit downregulated T-bet and MEG3 expression levels, respectively, with more pronounced effects in females. The gene discussed is MEG3; the disease is relapsing-remitting multiple sclerosis.